BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zilovertamab vedotin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zilovertamab vedotin\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05139017-9128@assetmemo.bio
DTSTAMP:20261121T004513Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Zilovertamab vedotin: Phase 2/3 readout est. (NCT05139017)
DESCRIPTION:Zilovertamab vedotin\, phase 2/3\, Diffuse Large B-Cell Lymphom
 a.\nStudy: A Study of Zilovertamab Vedotin (MK-2140) in Combination With S
 tandard of Care in Participants With Relapsed or Refractory Diffuse Large 
 B-Cell Lymphoma (rrDLBCL) (MK-2140-003)\nEstimated primary completion: 24 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zilov
 ertamab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05139017
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890884-9128@assetmemo.bio
DTSTAMP:20261121T004513Z
DTSTART;VALUE=DATE:20271213
DTEND;VALUE=DATE:20271214
SUMMARY:Zilovertamab vedotin: Phase 2 readout est. (NCT06890884)
DESCRIPTION:Zilovertamab vedotin\, phase 2\, Diffuse Large B-Cell Lymphoma.
 \nStudy: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab
  Plus Cyclophosphamide\, Doxorubicin\, and Prednisone (R-CHP) Versus Polat
 uzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DL
 BCL) (MK-2140-011/waveLINE-011)\nEstimated primary completion: 13 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/zilovertamab-v
 edotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06890884
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913594-9128@assetmemo.bio
DTSTAMP:20261121T004513Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Zilovertamab vedotin: Phase 2 readout est. (NCT07913594)
DESCRIPTION:Zilovertamab vedotin\, phase 2.\nStudy: Zilovertamab Vedotin an
 d Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell 
 Lymphoma\nEstimated primary completion: 31 December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07913594
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05562830-9128@assetmemo.bio
DTSTAMP:20261121T004513Z
DTSTART;VALUE=DATE:20290226
DTEND;VALUE=DATE:20290227
SUMMARY:Zilovertamab vedotin: Phase 1/2 readout est. (NCT05562830)
DESCRIPTION:Zilovertamab vedotin\, phase 1/2.\nStudy: A Substudy of Investi
 gational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory L
 ocally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)\nEs
 timated primary completion: 26 February 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05562830
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06395103-9128@assetmemo.bio
DTSTAMP:20261121T004513Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zilovertamab vedotin: Phase 1/2 readout est. (NCT06395103)
DESCRIPTION:Zilovertamab vedotin\, phase 1/2\, Diffuse Large B-Cell Lymphom
 a.\nStudy: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult
  Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/L
 IGHTBEAM-U01)\nEstimated primary completion: 31 March 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06395103
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05406401-9128@assetmemo.bio
DTSTAMP:20261121T004513Z
DTSTART;VALUE=DATE:20290426
DTEND;VALUE=DATE:20290427
SUMMARY:Zilovertamab vedotin: Phase 2 readout est. (NCT05406401)
DESCRIPTION:Zilovertamab vedotin\, phase 2\, Diffuse Large B-Cell Lymphoma.
 \nStudy: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyc
 lophosphamide\, Doxorubicin\, and Prednisone Plus Rituximab or Rituximab B
 iosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymp
 homa (DLBCL) (MK-2140-007)\nEstimated primary completion: 26 April 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zilovertamab-vedotin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05406
 401
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05458297-9128@assetmemo.bio
DTSTAMP:20261121T004513Z
DTSTART;VALUE=DATE:20290517
DTEND;VALUE=DATE:20290518
SUMMARY:Zilovertamab vedotin: Phase 2 readout est. (NCT05458297)
DESCRIPTION:Zilovertamab vedotin\, phase 2.\nStudy: A Study of Zilovertamab
  Vedotin (MK-2140) as Monotherapy and in Combination in Participants With 
 Aggressive and Indolent B-cell Malignancies (MK-2140-006)\nEstimated prima
 ry completion: 17 May 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/zilovertamab-vedotin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05458297
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717347-9128@assetmemo.bio
DTSTAMP:20261121T004513Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Zilovertamab vedotin: Phase 3 readout est. (NCT06717347)
DESCRIPTION:Zilovertamab vedotin\, phase 3\, Diffuse Large B-Cell Lymphoma.
 \nStudy: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination Wi
 th Rituximab Plus Cyclophosphamide\, Doxorubicin\, and Prednisone (R-CHP) 
 Versus Rituximab Plus Cyclophosphamide\, Doxorubicin\, Vincristine\, and P
 rednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-214
 0-010)\nEstimated primary completion: 2 July 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06717347
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917754-9128@assetmemo.bio
DTSTAMP:20261121T004513Z
DTSTART;VALUE=DATE:20370313
DTEND;VALUE=DATE:20370314
SUMMARY:Zilovertamab vedotin: Phase 2/3 readout est. (NCT07917754)
DESCRIPTION:Zilovertamab vedotin\, phase 2/3\, Diffuse Large B-Cell Lymphom
 a.\nStudy: A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Partic
 ipants With Diffuse Large B-cell Lymphoma (MK-1045-010)\nEstimated primary
  completion: 13 March 2037. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/zilovertamab-vedotin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07917754
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
